You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing Software for Pharmacodynamics and Bioassay Studies
SBC: TConneX Inc. Topic: DHP16C001Thegoal is to develop asoftwaretool that implementsa novelapproach applicableto fitgeneral pharmacologic, toxicology, or other biomedical data, that mayexhibita non-monotonic dose-responserelationship for which thecurrent parametricmodels fail. Thesoftwareexplores dose-responserelationships using both monotonicand non-monotonicmodels,and estimates theassociated doseresponsecurves,which can further ...
STTR Phase II 2019 Department of DefenseDefense Health Agency -
Medications for Synthetic Cannabinoid Abuse
SBC: PAFOSPharma, LLC Topic: R41PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Mechanical generation of peri-valvular oscillatory flow to prevent deep venous thrombosis.
SBC: OSCIFLEX LLC Topic: NHLBIProject SummaryDeep venous thrombosisDVTand secondary pulmonary embolismPEaffectof the population and cause approximatelydeaths annually in the USImmobility and lack of muscular activity is the primary risk factor for DVTan effect attributed to reduced venous flowAutopsy studies have identified the venous valve sinus in the leg as the site of origin for DVTbut a molecular and cellular mechanism fo ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction
SBC: IMMUNOCHEM THERAPEUTICS LLC Topic: 102PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a tracheal sound sensor for early detection of hypoventilation due to opioid overdose.
SBC: RTM Vital Signs, LLC Topic: R41Abstract More thanAmericans died from drug overdose inand drug overdose is now the most common cause of death for people underyears old in the United StatesFurthermorethe number of overdose deaths is increasing with the rise of abuse of powerful synthetic opioidssuch as fentanylIn May ofNational Institutes of HealthNIHand National Institute on Drug AbuseNIDAdirectors DrsCollins and Volkow outlined ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIDCRKaposi SarcomaKSis the most common cancer in themillion worldwide AIDS populationKS tumors are caused by Kaposi Sarcoma Associated Herpes VirusKSHVEven though HAART therapy has resulted in a dramatic decline in KS in the USthis malignancy remains the most predominant tumor of AIDSParadoxicallyKS tumors arise in some AIDS patients following HAART treatmentdue to Immune Reconstitution Inflammatory S ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Scalable Manufacturing Process for an Oral Bacteriophage Product that Prevents Cholera
SBC: PHAGEPRO, INC. Topic: NIAIDPROJECT SUMMARY Cholera is an acute and severe disease caused by the bacterium Vibrio cholerae that is spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructure. The World Health Organization estimates that there are at least 3 million cases globally per year, 40 percent of which are spread through household transmission. Current prevention methods req ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases
SBC: MAKSCIENTIFIC Topic: 400RESEARCH andampRELATEDUnitPROJECT SUMMARY ABSTRACT In response to PAthe aim of this Phase I STTR proposal is to optimize and develop peripherally actingcannabinoidreceptorCB Rneutral antagonists displaying favorable therapeutic profiles for treating diabetic nephropathyDNDN is a chronic diabetic kidney disease and affectstypeand typediabetic patientsIt is characterized by persistent albuminuria an ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Automated Rodent Research Home Cage Monitoring System for Animal Welfare
SBC: TRICORDER ARRAY TECHNOLOGIES LLC Topic: 100PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBIIdiopathic pulmonary fibrosis (IPF), the most common of the interstitial lung diseases, occurs in about 128,000 people, with 48,000 new cases diagnosed annually in the US. The typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandapos; of the lungs causing an irreversible loss of the tissueandapos;s ability to transport oxygen. Co-morbid pulmonary ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health